

Biodesix to acquire Oncimmune lab

October 2019—Biodesix (Boulder, Colo.) announced that it will acquire Oncimmune's U.S. operations, which include a CLIA lab in De Soto, Kan., and the company's incidental pulmonary nodule malignancy test, Early-CDT Lung.

"Oncimmune's extensive experience and patent portfolio in autoantibodies, and their relationship to cancer, attracted us to evaluate the use of Oncimmune's EarlyCDT Lung test as a strategic addition to our diagnostic test offering in the U.S.," David Brunel, CEO of Biodesix, said in a press release.

Biodesix's Nodify XL2 test is used to help rule out malignancy in low- to moderate-risk incidental lung nodules.

[Biodesix](#), 303-417-0500